BioSpace News Archive

Gilead Sciences officially announced that long-time Roche veteran, Daniel O’Day, will assume the helm of the company as chairman and chief executive officer beginning March 1. O’Day takes over for John Milligan, who announced his plans to retire by the end of the year in July.

Researchers published an article in the journal Nature Ecology & Evolution that described preliminary findings of gene variants in George associated with a strong immune system, efficient DNA repair and cancer resistance.

There is very little doubt that developing drugs for neuroscience disorders in general and dementias in particular is a high-risk business. Axovant Sciences, unfortunately, seems to be finding that out the hard way.

This morning the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that shows there are nearly 300 novel cell and gene therapies currently in development throughout the industry. The therapies are being studied as treatments for a variety of diseases and conditions.

At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.

According to consultant firm Frost & Sullivan, artificial intelligence (AI) systems will be the next big players in both global healthcare and individual gene editing. By 2021, the firm predicts that AI will be responsible for 6.7 billion dollars in revenue.

The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are often well-paying jobs for skilled workers.

Technology is constantly impacting and changing the way the world works. Greater technological innovations are not only changing the way business operate, but also have significant impact on employees.